Introduction
Sickle-cell disease (SCD) results from a variety of inherited genetic
mutations in the hemoglobin-beta (HBB) gene resulting in defective
beta-globin synthesis and culminating in attenuated oxygen transport
(1). One particular HBB gene mutation produces an altered beta-globin
molecule known as hemoglobin S (Hb S) with reduced oxygen delivery to
end-organs.
Being regarded as a rare clinical entity, SCD in patients who need open
heart surgery at large is poorly addressed in literature (2). With
diagnostic techniques’advancement, we have encountered many patients
with SCD associated with advanced heart failure that necessitates left
ventricular assist device (LVAD) implantation. The aim of our present
study was to evaluate the outcome of patients with SCD-related
hemoglobinopathy undergoing LVAD implantation at our institution and
then followed up after hospital discharge. Hence, we decided to
retrospectively look into our data to evaluate the outcomes of LVAD
implantation in this type of patients .